Panobinostat
- Generic Name
- Panobinostat
- Brand Names
- Farydak
- Drug Type
- Small Molecule
- Chemical Formula
- C21H23N3O2
- CAS Number
- 404950-80-7
- Unique Ingredient Identifier
- 9647FM7Y3Z
- Background
Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted. Panobinostat is mar...
- Indication
Panobinostat is indicated in the treatment of multiple myeloma in combination with dexamethasone and bortezomib in patients who have received 2 previous treatment regimens including bortezomib and an immunomodulatory agent. This indication is approved by accelerated approval based on progression free survival as of February 23, 2015.
- Associated Conditions
- Refractory Multiple Myeloma
- Associated Therapies
- -
A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients
- Conditions
- Interventions
- First Posted Date
- 2012-06-07
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 10
- Registration Number
- NCT01613976
- Locations
- ๐ฏ๐ต
Novartis Investigative Site, Kyoto, Japan
Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate
- Conditions
- Interventions
- First Posted Date
- 2012-04-20
- Last Posted Date
- 2022-08-15
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 26
- Registration Number
- NCT01582009
- Locations
- ๐บ๐ธ
University of Rochester Medical Center, Rochester, New York, United States
๐บ๐ธRoswell Park Cancer Institute, Buffalo, New York, United States
Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &/or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2012-03-09
- Last Posted Date
- 2019-01-16
- Lead Sponsor
- Emory University
- Target Recruit Count
- 32
- Registration Number
- NCT01549431
- Locations
- ๐บ๐ธ
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
๐บ๐ธEmory University Winship Cancer Institute, Atlanta, Georgia, United States
๐บ๐ธUniversity of Chicago, Chicago, Illinois, United States
Oral Panobinostat Adult Patients DLBCL Relapsed/Refractory Stem Cell Transfusion (ASCT) or Not Eligible for ASCT
- First Posted Date
- 2012-02-01
- Last Posted Date
- 2019-11-22
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 35
- Registration Number
- NCT01523834
- Locations
- ๐ฎ๐น
Azienda Ospedaliera SS. Antonio e Biagio e C. Arrigo, Alessandria, Italy
๐ฎ๐นIstituto di Ematologia ed Oncologia Medica A. Seragnoli Policlinico S. Orsola, Bologna, Italy
๐ฎ๐นOspedale Umberto I - DH Oncoematologico, Nocera Inferiore, Italy
Phase I Study of Panobinostat + Bortezomib for Relapsed and/or Refractory Mantle Cell Lymphoma (MCL)
- First Posted Date
- 2012-01-05
- Last Posted Date
- 2014-09-19
- Lead Sponsor
- Anand Jillella
- Target Recruit Count
- 3
- Registration Number
- NCT01504776
- Locations
- ๐บ๐ธ
Georgia Regents University, Augusta, Georgia, United States
Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma
- First Posted Date
- 2011-12-21
- Last Posted Date
- 2022-02-02
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 80
- Registration Number
- NCT01496118
- Locations
- ๐บ๐ธ
Florida Cancer Specialists South, Fort Myers, Florida, United States
๐บ๐ธTennessee Oncology-Chattanooga, Chattanooga, Tennessee, United States
๐บ๐ธTennessee Oncology, Nashville, Tennessee, United States
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2011-11-01
- Last Posted Date
- 2019-04-22
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 29
- Registration Number
- NCT01463046
- Locations
- ๐บ๐ธ
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2011-10-27
- Last Posted Date
- 2017-11-14
- Target Recruit Count
- 24
- Registration Number
- NCT01460940
- Locations
- ๐บ๐ธ
The Ohio State University Medical Center, Columbus, Ohio, United States
๐บ๐ธWashington University, Saint Louis, Missouri, United States
Phase I/II Study With Oral Panobinostat Maintenance Therapy Following Allogeneic Stem Cell Transplantation in Patients With High Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)
- First Posted Date
- 2011-10-13
- Last Posted Date
- 2018-03-20
- Lead Sponsor
- Johann Wolfgang Goethe University Hospital
- Target Recruit Count
- 62
- Registration Number
- NCT01451268
- Locations
- ๐ฉ๐ช
University Hospital Hamburg-Eppendorf, Hamburg, Germany
๐ฉ๐ชUniversity Hospital Mainz, Mainz, Germany
๐ฉ๐ชUniversity Hospital Frankfurt, Frankfurt am Main, Germany
Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients
- Conditions
- Interventions
- First Posted Date
- 2011-09-26
- Last Posted Date
- 2019-03-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 77
- Registration Number
- NCT01440582
- Locations
- ๐บ๐ธ
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.